Author
Listed:
- Rouven Hoefflin
(Section of Molecular Urooncology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg)
- Bernd Lahrmann
(Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BioQuant, University of Heidelberg)
- Gregor Warsow
(German Cancer Research Center (DKFZ))
- Daniel Hübschmann
(German Cancer Research Center (DKFZ)
Institute for Pharmacy and Molecular Biotechnology (IPMB) and BioQuant, University of Heidelberg
Hematology and Oncology, University Hospital Heidelberg)
- Cathleen Spath
(National Center for Tumor Diseases)
- Britta Walter
(University of Heidelberg School of Medicine)
- Xin Chen
(Section of Molecular Urooncology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg)
- Luisa Hofer
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Stephan Macher-Goeppinger
(University of Heidelberg School of Medicine
Present address: Department of Pathology, University of Mainz Medical School, Langenbeckstrasse 1, D-55131 Mainz, Germany)
- Yanis Tolstov
(Section of Molecular Urooncology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg)
- Nina Korzeniewski
(Section of Molecular Urooncology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg)
- Anette Duensing
(University of Pittsburgh Cancer Institute, Cancer Therapeutics Program)
- Carsten Grüllich
(National Center for Tumor Diseases
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Dirk Jäger
(National Center for Tumor Diseases
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Sven Perner
(Institute of Pathology, University Hospital Lübeck and Leibniz Research Center Borstel)
- Gita Schönberg
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Joanne Nyarangi-Dix
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Sanjay Isaac
(National Center for Tumor Diseases
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Gencay Hatiboglu
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Dogu Teber
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Boris Hadaschik
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Sascha Pahernik
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine
Present address: Department of Urology, Nuremberg Hospital, Paracelsus Medical University, Prof.-Ernst-Nathan-Strasse 1, D-90419 Nuremberg, Germany)
- Wilfried Roth
(University of Heidelberg School of Medicine
Present address: Department of Pathology, University of Mainz Medical School, Langenbeckstrasse 1, D-55131 Mainz, Germany)
- Roland Eils
(German Cancer Research Center (DKFZ)
Institute for Pharmacy and Molecular Biotechnology (IPMB) and BioQuant, University of Heidelberg)
- Matthias Schlesner
(German Cancer Research Center (DKFZ))
- Holger Sültmann
(National Center for Tumor Diseases, German Cancer Research Center, German Cancer Consortium (DKTK))
- Markus Hohenfellner
(University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
- Niels Grabe
(Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BioQuant, University of Heidelberg)
- Stefan Duensing
(Section of Molecular Urooncology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg
University of Heidelberg School of Medicine
Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine)
Abstract
Intratumoural heterogeneity (ITH) is a major cause of cancer-associated lethality. Extensive genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC). Here we address the question whether ITH increases with malignant progression and can hence be exploited as a prognostic marker. Unexpectedly, precision quantitative image analysis reveals that the degree of functional ITH is virtually identical between primary ccRCCs of the lowest stage and advanced, metastatic tumours. Functional ITH was found to show a stage-independent topological pattern with peak proliferative and signalling activities almost exclusively in the tumour periphery. Exome sequencing of matching peripheral and central primary tumour specimens reveals various region-specific mutations. However, these mutations cannot directly explain the zonal pattern suggesting a role of microenvironmental factors in shaping functional ITH. In conclusion, our results indicate that ITH is an early and general characteristic of malignant growth rather than a consequence of malignant progression.
Suggested Citation
Rouven Hoefflin & Bernd Lahrmann & Gregor Warsow & Daniel Hübschmann & Cathleen Spath & Britta Walter & Xin Chen & Luisa Hofer & Stephan Macher-Goeppinger & Yanis Tolstov & Nina Korzeniewski & Anette , 2016.
"Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity,"
Nature Communications, Nature, vol. 7(1), pages 1-12, September.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11845
DOI: 10.1038/ncomms11845
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11845. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.